<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="363111">
  <stage>Registered</stage>
  <submitdate>3/10/2012</submitdate>
  <approvaldate>4/10/2012</approvaldate>
  <actrnumber>ACTRN12612001063808</actrnumber>
  <trial_identification>
    <studytitle>Investigation of the effect of cryoprecipitate (blood plasma product that can help blood to clot)  transfusion on coagulation  abnormalities after open heart, aortic surgeries</studytitle>
    <scientifictitle>Fibrinogen recovery and FIBTEM changes after cryoprecipitate transfusion in patients undergoing aortic surgery involving deep hypothermic circulatory arrest</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>none</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>patients undergoing elective or emergency aortic surgery involving deep hypothermic circulatory arrest (DHCA) during cardiopulmonary bypass (CPB)</healthcondition>
    <conditioncode>
      <conditioncode1>Anaesthesiology</conditioncode1>
      <conditioncode2>Other anaesthesiology</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Blood</conditioncode1>
      <conditioncode2>Clotting disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Surgery</conditioncode1>
      <conditioncode2>Other surgery</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>1. If considered appropriate clinically and with laboratory (FIBTEM A10 result), 10 units of cryoprecipitate (350-400ml /10 units) are transfused 5-10 minutes after protamine administration at the end of cardiopulmonary bypass (CPB) weaning.
2. 10 units of cryoprecipitates are given over 20-30 minutes.
3. 10 minutes after completion of cryoprecipitate transfusion, the following test are done.
-  platelet count, PT, INR, aPTT, fibrinogen
 - ROTEM parameters :  coagulation time (CT), alpha angle, clot amplitude A10 (amplitude at 10 minutes after clotting initiation) in extrinsically-activated EXTEM and fibrin-based FIBTEM</interventions>
    <comparator>This study is a single group trial.
This study is to see the effect of cryoprecipitate transfusion, therefore compares before and after transfusion.</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Changes in clot amplitude A10 (amplitude at 10 minutes after clotting initiation) in fibrin-based FIBTEM</outcome>
      <timepoint>10 minutes after cryoprecipitate transfusion</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Changes in clotting time (CT) in extrinsically-activated EXTEM</outcome>
      <timepoint>10 minutes after cryoprecipitate transfusion</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Changes in alpha angle in extrinsically-activated EXTEM</outcome>
      <timepoint>10 minutes after cryoprecipitate transfusion</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Changes in clot amplitude A10 (amplitude at 10 minutes after clotting initiation) in extrinsically-activated EXTEM</outcome>
      <timepoint>10 minutes after cryoprecipitate transfusion</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Elective or emergency aortic surgery involving deep hypothermic circulatory arrest (DHCA) during cardiopulmonary bypass (CPB)</inclusivecriteria>
    <inclusiveminage>20</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>80</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Patients were excluded from the study if they revealed severe hypofibrinogenemia preoperatively, indicated by serum fibrinogen &lt; 50mg/dl or FIBTEM &lt; 1, or if the patients were not indicated to receive cryoprecipitate transfusion after protamine reversal.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>27/12/2009</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>10</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Korea, Republic Of</country>
      <state>Seoul</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Samsung Medical Center Clinical Research Development Program</primarysponsorname>
    <primarysponsoraddress>50 Ilwon Dong, Gangnam gu, 135-710
Samsung Medical Center</primarysponsoraddress>
    <primarysponsorcountry>Korea, Republic Of</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Samsung Medical Center Clinical Research Development Program</fundingname>
      <fundingaddress>50 Ilwon Dong, Gangnam gu, 135-710
Samsung Medical Center</fundingaddress>
      <fundingcountry>Korea, Republic Of</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Cryoprecipitate may be used as haemostatic agent in patients with bleeding following on-pump aortic surgery with deep hypothermic circulatory arrest (DHCA). Its effect on plasma fibrinogen concentration and fibrin clot quality has not been reported to date. Standard coagulation laboratory and ROTEM parameters including clotting time (CT), alpha angle (a), clot amplitude A10 (amplitude at 10 minutes after clotting initiation) in extrinsically-activated EXTEM and fibrin-based FIBTEM were evaluated before and after cryoprecipitate transfusion.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Samsung Medical Center Istitutional review board</ethicname>
      <ethicaddress>50 Ilwon Dong, Gangnam gu, 130-710
Samsung Medical Center</ethicaddress>
      <ethicapprovaldate>21/10/2009</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Korea, Republic Of</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Sang Hyun Lee</name>
      <address>Ilwon Dong, Gangnam gu, 135-710
Samsung Medical Center</address>
      <phone>+82-2-3410-2470</phone>
      <fax />
      <email>joy2sarah@yahoo.co.kr</email>
      <country>Korea, Republic Of</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Sang Hyun Lee</name>
      <address>Ilwon Dong, Gangnam gu, 135-710
Samsung Medical Center</address>
      <phone>+82-2-3410-2470</phone>
      <fax />
      <email>joy2sarah@yahoo.co.kr</email>
      <country>Korea, Republic Of</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Sang Hyun Lee</name>
      <address>Ilwon Dong, Gangnam gu, 135-710
Samsung Medical Center</address>
      <phone>+82-2-3410-2470</phone>
      <fax />
      <email>joy2sarah@yahoo.co.kr</email>
      <country>Korea, Republic Of</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>